Financial Contrast: Inogen and Neuronetics

Comparing two small-cap medical companies to determine the better investment

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Inogen (NASDAQ:INGN) and Neuronetics (NASDAQ:STIM) are both small-cap medical companies, but which one is the better investment? This article compares the two businesses based on factors like earnings, institutional ownership, valuation, risk, dividends, profitability, and analyst recommendations.

Why it matters

Understanding the financial performance and market positioning of small-cap medical companies like Inogen and Neuronetics can help investors make informed decisions about which stocks to include in their portfolios. The analysis provides insights into the relative strengths and weaknesses of these two firms.

The details

The article breaks down key metrics for Inogen and Neuronetics, including net margins, return on equity, return on assets, revenue, earnings per share, and valuation. It also looks at factors like stock price volatility, analyst ratings, and price targets. Overall, the data suggests that while Inogen has higher revenue and earnings, Neuronetics may have more upside potential based on analyst projections.

  • The article was published on March 9, 2026.

The players

Inogen, Inc.

A medical technology company that develops, manufactures, and markets portable oxygen concentrators for patients with chronic respiratory conditions.

Neuronetics, Inc.

A commercial stage medical technology company that designs, develops, and markets products for patients with neurohealth disorders, including its NeuroStar Advanced Therapy System for treating major depressive disorder.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the nuanced differences between two small-cap medical companies and the importance of carefully evaluating factors like financial performance, market positioning, and analyst sentiment when assessing investment opportunities in the healthcare sector.